BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study

BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.

Zacks Investment Research • Aug 20, 2026

BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire

FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.

PRNewsWire • Aug 17, 2026

Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing

Becton Dickinson gets its prior buy rating reaffirmed again, agreeing with the latest Wall St consensus. Key strengths are its diverse and growing clinical portfolio expected to drive further upside, while a favorable Fitch rating lowers balance sheet risk. Market performance vs the S&P 500 is improving again.

Seeking Alpha • Aug 13, 2026

Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH

Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.

Zacks Investment Research • Aug 13, 2026

BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial

Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.

PRNewsWire • Aug 12, 2026

We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays, arguing that boring income names carried real upside if the market ever noticed.

24/7 Wall Street • Aug 10, 2026

Becton, Dickinson and Company Q3 Earnings Call Highlights

Becton, Dickinson and Company NYSE: BDX reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company's expectations.

MarketBeat • Aug 8, 2026

Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript

Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

BD Reports Third Quarter Fiscal 2026 Financial Results

Revenue of $5.0 billion increased 5.4% as reported, 4.4% FXN GAAP and adjusted diluted EPS from continuing operations of $1.64 and $3.23, respectively Year-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billion Company updates full-year guidance to reflect ongoing momentum, expects revenue growth toward the high end of its range and raises midpoint of adjusted diluted EPS guidance FRANKLIN LAKES, N.J., Aug. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 third quarter, which ended June 30, 2026.

PRNewsWire • Aug 6, 2026

Becton Dickinson (BDX) Q3 Earnings and Revenues Surpass Estimates

Becton Dickinson (BDX) came out with quarterly earnings of $3.23 per share, beating the Zacks Consensus Estimate of $3.14 per share. This compares to earnings of $3.68 per share a year ago.

Zacks Investment Research • Aug 6, 2026